F18.97 Inhalant use, unspecified with inhalant-induced persisting dementia

Name of the Condition

• Common Name: Inhalant Use Disorder with Inhalant-Induced Persisting Dementia
• Medical Term: Inhalant use, unspecified with inhalant-induced persisting dementia

Summary

Inhalant use, unspecified with inhalant-induced persisting dementia, refers to the misuse of inhalants—substances that produce chemical vapors—for their psychoactive effects, accompanied by persistent cognitive impairment. This condition involves the intentional inhalation of substances like glue, paint thinners, or aerosols, which can lead to long-term neurological damage. Inhalant use may result in significant cognitive decline, affecting an individual's memory, reasoning, and daily functioning.

Causes

Inhalant use is primarily driven by the repeated misuse of inhalants for their psychoactive effects. Inhalants are often everyday household or industrial products, such as glue, paint thinners, aerosols, or solvents. The misuse of these substances can lead to dependence and related health issues, including irreversible neurological damage.

Risk Factors

• Adolescents and young adults are more likely to experiment with inhalants.
• Individuals with a history of substance abuse or mental health disorders.
• Accessibility to inhalant products.
• Lack of proper supervision or guidance.

Symptoms

• Intense cravings or compulsive inhalant use.
• Coordination problems, dizziness, or lethargy.
• Unexplained behavioral changes such as aggression or mood swings.
• Cognitive impairment, including memory loss or difficulty concentrating.
• Persistent confusion or disorientation.

Diagnosis

Diagnosis involves a comprehensive evaluation of the patient's history of inhalant use, clinical symptoms, and cognitive assessments. Healthcare providers may use standardized tests to assess memory, attention, and executive function. Imaging studies or laboratory tests may be conducted to rule out other causes of dementia. Documentation should reflect the persistence of cognitive symptoms and their link to inhalant use.

Treatment Options

Treatment focuses on managing cognitive symptoms and addressing inhalant use. Interventions may include cognitive rehabilitation, behavioral therapy, and support for substance use cessation. Medications may be prescribed to manage co-occurring conditions, such as anxiety or depression. Long-term care planning may be necessary for severe cases.

Prognosis and Follow-Up

Prognosis depends on the extent of cognitive damage and the success of treatment. Early intervention may slow progression, but some cognitive impairment may be permanent. Regular follow-up is essential to monitor cognitive function, substance use, and overall health. Support from family or caregivers is often critical for managing daily activities.

Complications

• Irreversible cognitive decline or dementia.
• Increased risk of accidents due to impaired coordination.
• Worsening of mental health conditions, such as depression or anxiety.
• Social or occupational dysfunction due to cognitive impairment.

Lifestyle & Prevention

• Avoiding inhalant use entirely is the most effective prevention strategy.
• Educating at-risk populations about the dangers of inhalants.
• Ensuring proper storage and supervision of household or industrial products.
• Seeking early intervention for substance use concerns.

When to Seek Professional Help

Seek professional help if you or someone you know experiences persistent cognitive symptoms, unexplained behavioral changes, or signs of inhalant use. Early evaluation can help manage symptoms and prevent further damage. Contact a healthcare provider or mental health professional for assessment and support.

Tips for Medical Coders

When coding for F18.97, ensure documentation clearly links inhalant use to persistent dementia. Include details about the type of inhalant, duration of use, and the presence of cognitive impairment. Verify that the dementia is attributed to inhalant use and not another cause. Accurate documentation supports appropriate coding and reflects the clinical severity of the condition.